Gsk Plc (GSK.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Sales | 8,409,000 | 7,629,000 | 8,618,000 | 8,547,000 | 7,986,000 |
| Cost of Goods | 2,266,000 | 1,875,000 | 2,657,000 | 2,258,000 | 2,165,000 |
| Gross Profit | 6,143,000 | 5,754,000 | 5,961,000 | 6,289,000 | 5,821,000 |
| Operating Expenses | 5,662,000 | 3,461,000 | 4,455,000 | 3,696,000 | 3,798,000 |
| Operating Income | 481,000 | 2,293,000 | 1,506,000 | 2,593,000 | 2,023,000 |
| Interest Expense | 182,000 | 167,000 | 174,000 | 167,000 | 184,000 |
| Other Income | 55,000 | 18,000 | -382,000 | 30,000 | 48,000 |
| Pre-tax Income | 354,000 | 2,144,000 | 950,000 | 2,456,000 | 1,887,000 |
| Income Tax | -199,000 | 305,000 | 223,000 | 312,000 | 241,000 |
| Net Income Continuous | 553,000 | 1,839,000 | 727,000 | 2,144,000 | 1,646,000 |
| Minority Interests | -118,000 | -102,000 | -91,000 | -131,000 | -203,000 |
| Net Income | $435,000 | $1,737,000 | $636,000 | $2,013,000 | $1,443,000 |
| EPS Basic Total Ops | 0.11 | 0.43 | 0.16 | 0.50 | 0.36 |
| EPS Basic Continuous Ops | 0.11 | 0.43 | 0.16 | 0.50 | 0.36 |
| EPS Diluted Total Ops | 0.11 | 0.43 | 0.16 | 0.49 | 0.35 |
| EPS Diluted Continuous Ops | 0.11 | 0.43 | 0.16 | 0.49 | 0.35 |
| EBITDA(a) | $2,826,000 | $2,774,000 | $1,124,000 | $3,361,000 | $3,230,000 |